Published in Int J Mol Sci on March 14, 2016
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update. Pharmaceuticals (Basel) (2016) 0.79
Advances in the development of aptamer drug conjugates for targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol (1999) 41.48
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36
Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem (1999) 5.22
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl (2006) 2.38
Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res (2006) 2.23
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Molecular recognition in the FMN-RNA aptamer complex. J Mol Biol (1996) 1.74
Oligonucleotide aptamers that recognize small molecules. Curr Opin Struct Biol (1999) 1.56
Challenges and opportunities for small molecule aptamer development. J Nucleic Acids (2012) 1.48
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci (2012) 1.40
Nanoparticle-mediated drug delivery and gene therapy. Biotechnol Prog (2007) 1.34
Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine (2011) 1.31
Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small (2011) 1.16
Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev (2010) 1.16
The permeability of SPION over an artificial three-layer membrane is enhanced by external magnetic field. J Nanobiotechnology (2006) 1.12
Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials (2010) 1.07
Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology (2002) 1.05
A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res (1998) 1.01
In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J (2000) 0.99
Silica-coated super paramagnetic iron oxide nanoparticles (SPION) as biocompatible contrast agent in biomedical photoacoustics. Biomed Opt Express (2012) 0.93
Macrophage labeling by SPIO as an early marker of allograft chronic rejection in a rat model of kidney transplantation. Magn Reson Med (2003) 0.91
Superparamagnetic iron oxide (SPIO) MRI contrast agent for bone marrow imaging: differentiating bone metastasis and osteomyelitis. Magn Reson Med Sci (2006) 0.91
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res (2001) 0.91
Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology (2005) 0.89
Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine (2012) 0.89
Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci (2013) 0.89
From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy. Anticancer Agents Med Chem (2006) 0.83
Selection of RNA aptamers specific to active prostate-specific antigen. Biotechnol Lett (2009) 0.82
Magnetic characterization of superparamagnetic nanoparticles pulled through model membranes. Biomagn Res Technol (2007) 0.82
A Novel Strategy for Surface Modification of Superparamagnetic Iron Oxide Nanoparticles for Lung Cancer Imaging. J Mater Chem (2009) 0.81
Targeted drug delivery for breast cancer treatment. Recent Pat Anticancer Drug Discov (2013) 0.80
Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern. Curr Pharm Des (2011) 0.80
Cardiotoxicity of oncological treatment in children. Adv Clin Exp Med (2012) 0.79
The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin Imaging (2006) 0.77
Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver. Magn Reson Med Sci (2005) 0.77
Easily controlled grafting of oligonucleotides on γFe2O3 nanoparticles: physicochemical characterization of DNA organization and biological activity studies. J Phys Chem B (2014) 0.77